OncoTherad(R) is an immunomodulator of biological response that downregulate RANK/RANKL signaling pathway and PD-1/PD-L1 immune checkpoint in non-muscle invasive bladder cancer

Autor(es)

Reis, Ianny Brum ; Soares Tibo, Luiz Henrique ; de Souza, Bianca Ribeiro ; Duran, Nelson ; Favaro, Wagner Jose

• Tipo de documento: Artigo Científico
• Fonte: JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY; v. N/A, p. 12-pg., 2022-11-02.

Resumo

Intoduction Bladder cancer is the second most common urinary tract cancer. Above 70% of the occurrence of bladder cancer is superficial (pTis, pTa, and pT1), non-muscle invasive tumor (NMIBC), and the incidence of invasive disease is occasional. Treatments for NMIBC consist of transurethral resection (TUR) and subsequently intravesical immunotherapy with Bacillus Calmette-Guerin (BCG), intending to prevent tumor progression and decrease recurrence. However, 20-30% of these tumors have progression, and 70% have a recurrence after exclusive TUR treatment. The immunomodulator of biological response, OncoTherad(R), is an attractive potential to revolutionize cancer therapy. In our previous studies with mice, the results showed that treatment with OncoTherad(R) reduced 100% of tumor progression in NMIBC through the activation of Toll-Like Receptors' non-canonical pathway. Materials and Methods In the present study, 36 female C57Bl/6J mice were divided into 6 groups (n = 6/group): Control, Cancer, Cancer + BCG, Cancer + OncoTherad(R) (MRB-CFI-1), Cancer + P14-16 and Cancer + CFI-1. NMIBC was chemically induced and the treatments were followed for 6 weeks. A week after the last dose of treatment, animals were euthanized, the bladder was collected and routinely processed for immunohistochemical analyses of RANK, RANKL, FOXP3, and PD-1/PD-L1, such as PD-1/PD-L1 western blotting. Conclusion The immunohistochemical results showed that OncoTherad(R) reduced RANK and RANKL immunoreactivities compared to the cancer group, which indicates a good prognosis. Immunohistochemical and western blotting analyses confirmed that OncoTherad(R) modulated PD-1/PD-L1 immune checkpoint. (AU)

• Processo FAPESP: 18/10052-1 - Novas Abordagens Terapêuticas para o Câncer de Bexiga Não-Músculo Invasivo (CBNMI): Uso Intravesical do Modificador de Resposta Biológica OncoTherad e Sua Associação com o Plasma Rico em Plaquetas (PRP)
• Beneficiário: Wagner José Fávaro
• Modalidade de apoio: Auxílio à Pesquisa - Regular
• Processo FAPESP: 20/03419-6 - Efeitos terapêuticos e toxicológicos da imunoterapia com OncoTherad (MRB-CFI-1) em pacientes com câncer de bexiga não-músculo invasivo recidivado não responsivo à terapia com Bacillus Calmette-Guérin (BCG)
• Beneficiário: Wagner José Fávaro
• Modalidade de apoio: Auxílio à Pesquisa - Regular